ATOS - Atossa Genetics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.0100
0.0000 (0.00%)
At close: 4:00PM EDT

2.0100 0.00 (0.00%)
After hours: 4:25PM EDT

Stock chart is not supported by your current browser
Previous Close2.0100
Open2.0100
Bid2.0000 x 800
Ask2.0100 x 3200
Day's Range1.9886 - 2.0800
52 Week Range0.8000 - 7.3900
Volume135,599
Avg. Volume409,178
Market Cap18.35M
Beta (3Y Monthly)4.28
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire

    Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

    SEATTLE, Sept. 06, 2019 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer.

  • GlobeNewswire

    Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

    Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that all participant activities have been completed in its Phase 1 clinical trial of a new proprietary modified-release oral tablet form of its Endoxifen. This is a very important study for Atossa as we plan to use the new modified-release oral tablet in our upcoming Phase 2 study to reduce breast density.

  • GlobeNewswire

    Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update

    SEATTLE, Aug. 13, 2019 -- Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast.

  • GlobeNewswire

    Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk

    In the Tedx UofW talk, Steven Quay, M.D., Ph.D., Atossa’s Chief Executive Officer outlines the journey of Atossa Genetics in identifying improved ways to identify women at high risk of breast cancer, using mammography to identify dense breast tissue.  Dr. Quay also details his experience with triumph, failure and perseverance while trying to prevent one of the world’s most common diseases: breast cancer.

  • GlobeNewswire

    Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests

    Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported that patients and their doctors can now visit the company’s website to obtain information about gaining access to the company’s proprietary Endoxifen pursuant to the FDA’s “Expanded Access” guidelines. The company’s website includes its  Expanded Access policy as well as an automated form that can be used by physicians to request that their patients be considered for this program: http://www.atossagenetics.com/clinical-trials/ - ea-form. Sometimes called "compassionate use", Expanded Access is a potential pathway for a physician to access an investigational medical product (drug, biologic, or medical device) for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available for their patient with a serious disease or condition, or an immediately life-threatening condition. For more information about this process, please see the FDA website: FDA Expanded Use Website.

  • GlobeNewswire

    Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated

    Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it is developing a new proprietary modified-release oral tablet form of its Endoxifen, which is the form of the drug that the company intends for future clinical studies and commercialization. This is the next generation of oral Endoxifen following the successful clinical studies of the capsule form of the company’s oral Endoxifen. Based on the abundance of information from our previous clinical studies, we strongly believe in the potential efficacy of oral dosing and intend for this modified-release tablet to be the commercial form of our oral Endoxifen.

  • GlobeNewswire

    Atossa Genetics’ Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density

    Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that a preliminary analysis from its recently completed Phase 2 study of the company’s proprietary 20mg daily topical Z Endoxifen (“Endoxifen”) showed significant and rapid reduction in mammographic breast density (MBD). Studies by others using tamoxifen have demonstrated that density reduction induced by tamoxifen is associated with a significant reduction in breast cancer incidence. MBD was reduced by an average of 14.3 percent in the group applying 20mg daily topical Endoxifen, which was statistically significant (p = 0.02).

  • GlobeNewswire

    Atossa Genetics to Present at the 9th Annual LD Micro Invitational on June 4, 2019

    SEATTLE, May 30, 2019 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and.

  • GlobeNewswire

    Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update

    SEATTLE, May 13, 2019 -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast.

  • ACCESSWIRE

    "The Digital Economy & World Markets"

    SAN FRANCISCO, CA / ACCESSWIRE / April 30, 2019 / Vista Partners ("Vista") has published April 2019's FREE Macroeconomic & Investment Monthly Newsletter, "The Digital Economy & World Markets." ...

  • GlobeNewswire

    Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit

    SEATTLE, April 25, 2019 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer.

  • ACCESSWIRE

    Reducing This Amino Acid May Aid In Fight Against Breast Cancer

    SAN FRANCISCO, CA / ACCESSWIRE / April 22, 2019 / According to The American Cancer Society ( ACS ) breast cancer is the most common cancer in American women, except for skin cancers. Currently, the average ...

  • GlobeNewswire

    Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019

    SEATTLE, April 22, 2019 -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer.

  • GlobeNewswire

    Atossa Genetics Announces Year End 2018 Financial Results and Provides Company Update

    SEATTLE, March 28, 2019 -- Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast.

  • ACCESSWIRE

    "Bull Market Hopping?"

    SAN FRANCISCO, CA / ACCESSWIRE / March 27, 2019 / Vista Partners ("Vista") has published March 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Bull Market Hopping?" Vista's ...

  • GlobeNewswire

    Atossa Genetics Announces Institutional Review Board Approval of Oral Endoxifen as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

    Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the Institutional Review Board (IRB) has approved the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient. "IRB approval was the final step in making our oral Endoxifen available to this patient,” commented Dr. Steven C. Quay, President and CEO of Atossa. “We are encouraged that the regulatory authorities recognize the potential for additional treatment options for pre-menopausal breast cancer patients.

  • GlobeNewswire

    Atossa Genetics Announces Receipt of $10 Million

    Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that on March 14 and 15, 2019, it received approximately $10 million from exercises of previously outstanding warrants. “The $10 million in cash proceeds significantly enhances our cash position and provides working capital for our ongoing and planned clinical studies,” commented Kyle Guse, CFO and General Counsel of Atossa Genetics.

  • GlobeNewswire

    Atossa Genetics Announces FDA Approval of Oral Endoxifen for “Expanded Access” as Post-Mastectomy Treatment for a U.S. Breast Cancer Patient

    Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that the FDA has issued a “Safe to Proceed” letter under their “expanded access” program permitting the use of Atossa’s oral Endoxifen as a post-mastectomy treatment in a pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient. This patient completed a 3-week course of Atossa’s oral Endoxifen prior to her surgery under an FDA-approved expanded access program. The tumor activity from the initial biopsy was compared to the tumor activity at surgery, finding that the cancer cell biological activity was reduced by two measures: the Ki-67 activity decreased by 50 percent, and the estrogen receptor content decreased by over 20 percent.

  • ACCESSWIRE

    "On Fed's Wings" Vista Partners Publishes February 2019's Macroeconomic & Investment Monthly Newsletter

    SAN FRANSISCO, CA / ACCESSWIRE / February 27, 2019 / Vista Partners ("Vista") has published February 2019's FREE Macroeconomic & Investment Monthly Newsletter, "On Fed's Wings." Vista's ...

  • GlobeNewswire

    Atossa Genetics Reports Results From “Expanded Access” Program for a U.S. Breast Cancer Patient Taking Oral Endoxifen: Sizeable Reduction in Cancer Cell Biological Activity; No Safety or Tolerability Issues

    SEATTLE, Feb. 07, 2019 (GLOBE NEWSWIRE) -- , February 7, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today updated the status of the pre-menopausal, estrogen-receptor positive (ER+) breast cancer patient who received preoperative oral Endoxifen therapy under an FDA-approved “expanded access” program. The purpose of this therapeutic approach was to reduce activity of the cancer cells prior to surgery. There were no safety or tolerability issues and her surgery was completed successfully.

  • GlobeNewswire

    Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force

    Atossa Genetics Inc. (ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced that it has provided suggested changes to the draft recommendation of the United States Preventative Services Task Force (USPSTF) concerning “Breast Cancer: Medications for Risk Reduction.” The public comment period ends February 11, 2019 and the finalized USPSTF recommendations will become available in July 2019. Mammographic breast density (MBD) provides the only patient level, biology-based assessment that is predictive of future breast cancer and it is modifiable.

  • ACCESSWIRE

    Vista Partners January 2019 Monthly Macroeconomic and Investment Newsletter

    SAN FRANSICO, CA / ACCESSWIRE / January 30, 2019 / Vista Partners ("Vista") has published January 2019's FREE Macroeconomic & Investment Monthly Newsletter, "Global Expansion Slows." ...

  • GlobeNewswire

    Atossa Genetics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2019

    In 2018, we completed our transformation into a Phase 2 clinical-stage pharmaceutical company. Building on that momentum, our 2019 goals are a three-fold, laser-focused clinical program to continue the development of novel therapeutics and delivery methods to: 1) treat breast cancer, 2) reduce the risk of breast cancer, and 3) prevent/reduce gynecomastia. Throughout 2018, we advanced our Endoxifen programs into Phase 2 clinical studies for estrogen receptor positive (ER+) breast cancer and executed a research and development program of immunotherapies (such as Chimeric Antigen Receptor Therapy, or CAR-T) intended for targeted delivery via our proprietary microcatheters for the potential treatment of “triple negative” breast cancer (TNBC) and BRCA+ breast cancer.

  • ACCESSWIRE

    Today's Research Reports on Trending Tickers: BioTelemetry and Atossa Genetics

    NEW YORK, NY / ACCESSWIRE / January 10, 2019 / U.S. markets rose for the fourth consecutive session on Wednesday as minutes released from the Federal Reserve's meeting in December showed the Fed would ...

  • ACCESSWIRE

    4 Healthcare Stocks Looking To Set January Highs

    CORAL GABLES, FL/ ACCESSWIRE / January 9, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Given that the world's population is consistently increasing, and resources are diminishing, access to healthcare is something crucial to the health and wellness of every living person, presenting a dire need for companies on a global scale. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare.